Pablo Luis Ortiz-Romero (P L Ortiz-Romero, Pablo L Ortiz-Romero, Pablo Ortiz-Romero)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 14

Top Topics

Hodgkin Lymphoma

Diffuse Large B Cell Lymphoma

Prognostic Factors

Top Venues

The British journal of dermatology

Nature medicine

Dermatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Steven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, Sean Whittaker, Madeleine Duvic, Youn H Kim, Pietro Quaglino, Pier Luigi Luigi Zinzani, Oliver Bechter, Herbert Eradat, Lauren Pinter-Brown, Oleg E Akilov, Larisa Geskin, Jose Antonio Sanches, Pablo Luis Ortiz-Romero, Michael Weichenthal, David C Fisher, Jan Walewski, Judith Trotman, Kerry Taylor, Stephane Dalle, Rudolf Stadler, Julie Lisano, Veronica Bunn, Meredith Little, Henry Miles Prince
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood advances 5 (23) (2022)
Daniel Falkenhain-López, Mario Puerta Peña, Jon Fulgencio-Barbarin, Alba Sánchez-Velázquez, Cristina Vico-Alonso, Concepción Postigo-Llorente, Pablo Luis Ortiz-Romero
Real-life experience of using pegylated liposomal doxorubicin in primary cutaneous T-cell lymphomas. Clinical and experimental dermatology 47 (9) (2022)
Claudio Giuliano, Stefano Frizzarin, Alessandro Alonzi, Virginia Stimamiglio, Pablo Luis Ortiz-Romero
Chlormethine Gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing. Dermatology and therapy 12 (11) (2022)
Kevin Molloy, Cristina Vico-Alonso, Pablo Luis Ortiz-Romero, Julia J Scarisbrick
Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome. The British journal of dermatology 184 (5) (2021)
Elise A Olsen, Sean Whittaker, Rein Willemze, Lauren Pinter-Brown, Francine M Foss, Larisa J Geskin, Lawrence Howard Schwartz, Steven M Horwitz, Joan Guitart, John Zic, Youn H Kim, Gary S Wood, Madeleine Duvic, Weiyun Z Ai, Michael Girardi, Alejandro A Gru, Emmanuella Guenova, Emmilia Hodak, Richard T Hoppe, Werner Kempf, Ellen J Kim, Mary Jo Lechowicz, Pablo Luis Ortiz-Romero, Evangelia Papadavid, Pietro Quaglino, Mark R Pittelkow, Henry Miles Prince, Jose Antonio Sanches, Makoto Sugaya, Maarten H Vermeer, Jasmine M Zain, Robert N A Knobler, Rudolf Stadler, Martine Bagot, Julia J Scarisbrick
Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. Blood (2021)
E Papadavid, Eirini Kapniari, V Pappa, Vasiliki A Nikolaou, T Iliakis, Maria Dalamaga, C Jonak, S Porkert, S Engelina, Pietro Quaglino, Pablo Luis Ortiz-Romero, Cristina Vico-Alonso, A Cozzio, Florentia Dimitriou, R Guiron, Emmanuella Guenova, E Hodak, Martine Bagot, Julia J Scarisbrick
Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity. The British journal of dermatology 185 (5) (2021)
David Olmeda, Daniela Cerezo-Wallis, Cynthia Mucientes, Tonantzin G Calvo, Estela Cañón, Direna Alonso-Curbelo, Nuria Ibarz, Javier Munoz, José Luis Rodriguez-Peralto, Pablo Luis Ortiz-Romero, Sagrario Ortega, María S Soengas
Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics. EMBO molecular medicine 13 (12) (2021)
Jorge Arroyo-Andres, Manuel Agud-Dios, Carmen A Rubio-Muniz, Cristina Vico-Alonso, Susana Cortijo-Cascajares, Pablo Luis Ortiz-Romero
Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report. International journal of dermatology (2021)
Nuria García-Díaz, Miguel Angel Piris, Pablo Luis Ortiz-Romero, José Pedro Vaqué
Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. Cancers 13 (8) (2021)
Pablo Luis Ortiz-Romero
The time for new biomarkers in mycosis fungoides/Sézary syndrome is here. The British journal of dermatology 185 (2) (2021)
Alba Sánchez-Velázquez, A Bauer-Alonso, Teresa Estrach, D Vega-Díez, Mª Pilar García-Muret, L Haya, Yeray Peñate, E Acebo, Ricardo Fernández-de-Misa, M Blanes, H J Suh-Oh, Rosa Maria Izu, E Silva-Díaz, J Sarriugarte, Concepción Román-Curto, Rafael Botella-Estrada, A Mateu-Puchades, L Prieto-Torres, V Morillas, M Morillo, P Sánchez-Caminero, L Calzado, A Pérez-Ferriols, A Pérez, J D Domínguez, M Navedo, C Muniesa, Andrea Combalia, Jorge Arroyo-Andres, Miguel Ángel Gallego Descalzo, Ignacio García Doval, Pablo Luis Ortiz-Romero
Patients with primary cutaneous lymphoma are at risk for severe COVID-19. Data from the Spanish Primary Cutaneous Lymphoma Registry. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (10) (2021)
Pablo Luis Ortiz-Romero, Octavio Servitje, María Teresa Estrach, Rosa María Izu-Belloso, Ricardo Fernández-de-Misa, Fernando Gallardo, Noemí López-Martínez, Alejandro Pérez-Mitru
Cost of early-stage mycosis fungoides treatments in Spain. ClinicoEconomics and outcomes research : CEOR 12 (2020)
Daniela Cerezo-Wallis, Marta Contreras-Alcalde, Kevin Troulé, Xavier Catena, Cynthia Mucientes, Tonantzin G Calvo, Estela Cañón, Cristina Tejedo, Paula C Pennacchi, Sabrina A Hogan, Peter Kölblinger, Héctor Tejero, Andrew X Chen, Nuria Ibarz, Osvaldo Graña-Castro, Lola Martinez, Javier Muñoz, Pablo Luis Ortiz-Romero, José L Rodriguez-Peralto, Gonzalo Gómez-López, Fátima Al-Shahrour, Raúl Rabadán, Mitchell P Levesque, David Olmeda, María S Soengas
Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nature medicine 26 (12) (2020)
Carla Solé, Daniela Tramonti, Maike Schramm, Ibai Goicoechea, María Armesto, Luiza I Hernandez, Lorea Manterola, Marta Fernández-Mercado, Karmele Mujika, Anna Tuneu, Ane Jaka, Maitena Tellaetxe-Abete, Marc R Friedländer, Xavier Estivill, Paolo Piazza, Pablo Luis Ortiz-Romero, Mark Ross Middleton, Charles H Lawrie
The Circulating Transcriptome as a Source of Biomarkers for Melanoma. Cancers 11 (1) (2019)